you could argue this from a different point of view. Ipps is an exploratory drug. If the pre-existing data at 2mg is of sufficient quality (agreed by PAR FDA ethics?), then why would subjects be subjected to this exploratory drug again. Ethics committee would not approve of this for the same reason that a trial is concluded early if interim analysis indicates the drug is going to pass its endpoints and it would be ethically unfair to inject the remaining subjects with a placebo.
My personal view is it points to the high quality of the data we have generated at our optimal dose.
Ann: PAR to present at NWR Healthcare Conference, page-26
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.55M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.0¢ | 20.5¢ | $222.5K | 1.035M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 77810 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 23000 | 2 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |